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Background
We recently reported the association between the Malmö sequence variant in F9 (rs6048)
and deep vein thrombosis.
Design and Methods
We aimed to study whether the association between F9 Malmö and deep vein thrombo-
sis is explained by linkage disequilibrium with nearby single-nucleotide polymorphisms,
and whether the association is explained biologically by F9 Malmö affecting factor IX anti-
gen levels or activation of factor IX. We investigated the association of F9 Malmö and 28
nearby single-nucleotide polymorphisms with deep vein thrombosis in men from two
case-control studies, LETS (n=380) and MEGA (n=1,469). We assessed the association of
F9 Malmö with factor IX antigen level in male control subjects from LETS (n=191) and two
subsets of MEGA (n=823 and n=484) and the association with endogenous thrombin
potential in LETS control men. We studied the association between F9 Malmö and factor
IX activation peptide in 1,199 healthy middle-aged men from the NPHS-II cohort.
Results
In the combined LETS and MEGA studies, the odds ratio (95% confidence interval) for the
G allele of F9 Malmö, compared with the A allele, was 0.80 (0.69-0.93). One single-
nucleotide polymorphism in F9, rs422187, was strongly linked to F9 Malmö (r2=0.94) and
was similarly associated with deep vein thrombosis. No other single-nucleotide polymor-
phism or haplotype tested was more strongly associated. Factor IX antigen level, factor IX
activation peptide levels and endogenous thrombin potential did not differ between F9
Malmö genotypes.
Conclusions
The F9 Malmö sequence variant was the most strongly associated with deep vein throm-
bosis among common single-nucleotide polymorphisms in the region. However, the bio-
logical mechanism by which F9 Malmö affects risk remains unknown.
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Introduction
The incidence rate of deep vein thrombosis in the gen-
eral population is estimated to be about 1 per 1,000 per-
son-years leading to 500,000 new cases per year in Europe
and 400,000 in the US.1,2 Deep vein thrombosis is a multi-
causal disease that results from acquired (e.g., age, oral
contraceptive use, surgery) and genetic risk factors (e.g.,
factor V Leiden, prothrombin G20210A). Elevated plasma
levels of coagulation factors (e.g., VIII,3 IX,4 X,5 and XI6)
have been shown to be important risk factors for deep
vein thrombosis. Antigen levels of factor IX above the 90th
percentile (129U/dL) have been associated with a 2 to 3-
fold increased risk of deep vein thrombosis.4 We recently
tested 19,682 potentially functional single-nucleotide
polymorphisms (SNPs) for association with deep vein
thrombosis.7 One of the SNPs identified was an A>G
sequence variant in the gene encoding factor IX (rs6048,
F9 Malmö) and the G allele was associated with a 15-43%
decrease in deep vein thrombosis risk compared with the
A allele, in three case-control studies of deep vein throm-
bosis. This common variant (minor allele frequency =
0.32) leads to the substitution of alanine for threonine at
amino acid position 148 in the portion of the factor IX
zymogen that is cleaved from the zymogen to activate
factor IX.8 This variant has not been reported to be associ-
ated with hemophilia B. The mechanism by which F9
Malmö affects risk of deep vein thrombosis is unclear. 
In this study we calculated the pooled odds ratios in the
case-control studies in which the association of F9 Malmö
with deep vein thrombosis was initially identified. We
investigated whether the association between F9 Malmö
and deep vein thrombosis could be explained by linkage
disequilibrium between F9 Malmö and other F9 variants.
We assessed whether the association could be explained
biologically by F9 Malmö affecting factor IX antigen levels,
activation of factor IX or endogenous thrombin potential.
Design and Methods
Study populations and data collection
The case-control populations (LETS, MEGA-1 and
MEGA-2) used to analyze the association of genotypes
with deep vein thrombosis are derived from two large
population-based case-control studies; the Leiden
Thrombophilia Study (LETS) and the Multiple
Environmental and Genetic Assessment (MEGA) of risk
factors for venous thrombosis. Samples from the
Northwick Park Heart Study–II (NPHS-II) were used to
evaluate the association of F9 Malmö genotype with fac-
tor IX activation peptide.
Collection and ascertainment of events in LETS have
been described previously.9 Briefly, patients were recruit-
ed between January 1, 1988 and December 30, 1992 from
three anticoagulation clinics in the western part of the
Netherlands: Leiden, Amsterdam, and Rotterdam. A total
of 474 consecutive patients, 70 years or younger, with a
diagnosis of a first deep vein thrombosis of the leg and
without a known malignancy were included. For each
patient, an age- (±5 years) and sex-matched control sub-
ject who had no history of deep vein thrombosis was
enrolled. In the present analysis of LETS, we excluded 52
participants due to inadequate quantity or quality of
DNA. After these exclusions, 443 patients and 453 con-
trols remained.
Collection and ascertainment of events in MEGA have
been described previously.10,11 Briefly, MEGA enrolled
consecutive patients aged 18-70 years who presented
with a first diagnosis of deep vein thrombosis in leg or
arm or pulmonary embolism at any of six anticoagulation
clinics in the Netherlands (Amsterdam, Amersfoort, The
Hague, Leiden, Rotterdam, and Utrecht) between March
1st, 1999 and May 31st, 2004. Control subjects in MEGA
included partners of patients and random population con-
trol subjects frequency-matched on age and sex to the
patient group and were selected so that the distribution of
age and sex matched that of the patient group. For the
present analyses we excluded patients who had a pul-
monary embolism without a documented deep vein
thrombosis or a history of malignant disorders to obtain
a study population similar to the LETS population. We
split the MEGA study to form two case-control studies,
based on recruitment date and sample availability (blood
or buccal swab). The first subset of MEGA, MEGA-1,
included 1,398 patients and 1,757 controls who donated a
blood sample. The remaining 1,314 patients and 2,877
controls, who donated either a blood sample or a buccal
swab sample, were included in MEGA-2.
We calculated the pooled odds ratio for deep vein
thrombosis in men and women from the LETS and
MEGA studies. The gene effect in men, who have one X-
chromosome, was assumed to be equivalent to the effect
in women homozygous for one allele, compared to
women homozygous for the other allele. Heterozygous
women were assumed to have an in-between gene effect.
The analysis of gene variants in F9 and deep vein throm-
bosis risk was restricted to men. The analysis of F9
Malmö with factor IX antigen levels and endogenous
thrombin potential, was restricted to men not using vita-
min K antagonists. The LETS study included 188 male
patients and 192 control men (191 with factor IX antigen
level measurements and 157 with endogenous thrombin
potential measurements), the MEGA-1 study included
637 male patients and 832 control men (823 with factor
IX antigen level measurements) and the MEGA-2 study
included 620 male patients and 1,327 control men (484
with factor IX antigen level measurements).
The Northwick Park Heart Study-II (NPHS-II) has been
described previously.12 Briefly, a cohort of 4,600 men aged
50-63 years registered with 9 general medical practices in
England and Scotland were screened for eligibility in the
NPHS-II. Exclusion criteria for the original study included:
a history of unstable angina or acute myocardial infarc-
tion (AMI); a major Q wave on the electrocardiogram
(ECG); regular aspirin or anticoagulant therapy; cere-
brovascular disease; life-threatening malignancy; condi-
tions exposing staff to risk or precluding informed con-
sent. Factor IX activation peptide was measured in the
first available sample from individuals who, at the time of
sampling, had not had a coronary heart disease event.
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Gene variants in the F9 region and risk of deep vein
thrombosis
To investigate whether other SNPs in this region might
be associated with deep vein thrombosis, we used results
from the HapMap Project to identify a region defined by
linkage disequilibrium with F9 Malmö (r2≥0.2, chr X:
138,404,951 to 138,494,063). Apart from the F9 gene, this
region also contains part of the gene encoding MCF.2 cell
line derived transforming sequence (MCF2). This region
contained 48 SNPs with allele frequencies >0.02
(HapMap data release #221, phase II April07, on NCBI
B36 assembly, dbSNP 126). Allele frequencies and linkage
disequilibrium were calculated from the SNP genotypes
in the HapMap CEPH population, which includes Utah
residents with ancestry from Northern and Western
Europe. Eighteen SNPs were selected for genotyping
using pairwise tagging in Tagger (implemented in
Haploview).13 We were unable to construct assays for 3
(rs4149754, rs438601, rs17340148) of the 18 tag SNPs;
the remaining 15 SNPs are reasonable surrogates for 45
of the 48 SNPs in this region because the 45 SNPs are
either directly genotyped or in strong linkage disequilib-
rium (r2>0.8) with at least one of the 15 genotyped SNPs.
In addition, we genotyped 14 candidate SNPs.14,15 Thus,
in total 29 SNPs were initially investigated in the men of
LETS. SNPs that were associated with deep vein throm-
bosis were subsequently investigated in the men of
MEGA-1.
Factor IX antigen level
The levels of factor IX were determined in LETS and
MEGA by enzyme-linked immunosorbent assay (ELISA)
as previously described.4 This ELISA is highly specific for
factor IX and results are not affected by the levels of the
other vitamin K–dependent proteins. The intra-assay and
interassay coefficients of variation were 7% and 7%,
respectively, in LETS and 4 % and 3% in MEGA. Results
are expressed in units per deciliter (dL), where 100 U is
the amount of factor IX present in 1 dL pooled normal
plasma.
Factor IX activation peptide 
Factor IX activation peptide was determined by double
antibody radioimmunoassay16 as a marker of turnover of
factor IX in the NPHS-II samples. The intra-assay coeffi-
cient of variation was less than 5% and the interassay
coefficient of variation was about 10% for factor IX acti-
vation peptide. 
F9 Malmö and endogenous thrombin potential
Endogenous thrombin potential is an activate protein
C (APC) sensitivity test that quantifies the time integral
of thrombin generated in plasma in which coagulation is
initiated via the extrinsic pathway.17,18 The sensitivity of
the plasma endogenous thrombin potential to APC was
measured in LETS under conditions where the test is
insensitive for small amounts of phospholipid present in
plasma as previously described.19,20
Allele frequency and genotype determination
DNA concentrations were standardized to 10 ng/µL
using PicoGreen (Molecular Probes, Invitrogen Corp,
Carlsbad, CA, USA) fluorescent dye. Genotyping of indi-
vidual DNA samples was performed as previously
described7 using 0.3ng of DNA in kPCR assays21 or using
multiplexed oligo ligation assays (OLA).22 Genotyping
accuracy of the multiplex methodology and kPCR has
been assessed in three previous studies by comparing
genotype calls from multiplex OLA assays with those
from real time kPCR assays for the same SNPs, and the
overall concordance of the genotype calls from these two
methods was >99% in each of these studies.23-25 Primer
sequences are available upon request. 
Statistical analysis 
The combined analysis of F9 Malmö in LETS, MEGA-
1 and MEGA-2 was performed using the meta package
version 0.8-2 available in R software language version
2.4.1 (http://www.r-project.org) by treating the individual
studies as fixed effects and using the inverse variance
method to estimate the pooled effect of the SNP.26
Deviations from Hardy–Weinberg expectations were
assessed using an exact test in controls. Odds ratios (OR)
and 95% confidence intervals (95% CI) were computed
as an estimate of risk of deep vein thrombosis associated
with each SNP using logistic regression. 
The association between haplotype and deep vein
thrombosis was assessed using the R language package
(http://cran.us.r-project.org/) of haplo.stats,27 which uses the
expectation maximization algorithm to estimate haplo-
type frequencies followed by testing for association
between haplotype and disease using a score test. A slid-
ing window was used to select and test haplotypes con-
sisting of 3, 5, and 7 adjacent SNPs from the set of SNPs
including F9 Malmö and the 28 other SNPs.
Differences in the factor IX antigen level and endoge-
nous thrombin potential between F9 Malmö genotypes
were assessed in control subjects of LETS, MEGA-1 and
MEGA-2 using a t-test assuming equal variance among
the groups. Differences in factor IX activation peptide
between F9 Malmö genotypes in NPHS-II were also
assessed using a t-test. t-tests were performed with SAS
version 9. Power to detect a difference in mean factor IX
antigen levels, activation peptide or thrombin potential
between F9 Malmö genotypes was calculated using
nQuery Advisor version 4.028 for a two sample t-test at a
0.05 two-sided significance level and assuming equal
variance among the groups.
Results
Combined analysis of F9 Malmö and deep vein
thrombosis 
In the combined analysis of LETS, MEGA-1 and
MEGA-2, we found that F9 Malmö was associated with
deep vein thrombosis in men: the pooled odds ratio was
0.80 (95% CI, 0.69-0.93) for the G (n=1,108) compared
with the A genotype (n=2,688). The pooled correspon-
ding odds ratio in women was 0.89 (95% CI, 0.74-1.08)
for the GG (n=405) compared with the AA genotypes
(n=2,190), assuming an in-between effect in heterozy-
gous women (n=1,750) (Figure 1). 
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Factor IX antigen level and risk of deep vein 
thrombosis
Factor IX antigen levels in LETS were previously report-
ed to be positively associated with risk of deep vein
thrombosis. Individuals with factor IX levels above the
90th percentile of the control group levels had a 2- to 3-fold
higher risk of deep vein thrombosis.4 In the MEGA study,
we confirmed the results published for LETS. We found
that individuals with factor IX antigen levels above the
90th percentile had a 1.7-fold (95% CI 1.4-2.1) increased
risk of deep vein thrombosis, compared with those with
levels below the 90th percentile. After adjustment for age,
sex, oral contraceptive use and vitamin K-dependent coag-
ulation factors II, VII and X (all coagulation factors
dichotomized at the 90th percentile) the odds ratio was 1.8
(95% CI 1.4-2.2). Among men, the unadjusted odds ratio
in the MEGA study was 1.8 (95%CI 1.3-2.4).
Gene variants in F9 region
To study the region surrounding F9 Malmö we investi-
gated 15 tag SNPs that served as surrogates for other SNPs
in the region and 14 additional candidate SNPs in LETS
men (Figure 2). We found that 7 of the 29 SNPs, including
F9 Malmö, were associated (p≤0.05) with deep vein
thrombosis (Table 1). We then investigated the association
between these 7 SNPs and deep vein thrombosis in
MEGA-1 men and found that 2 were significantly associ-
ated with deep vein thrombosis in MEGA-1: F9 Malmö
and rs422187, a SNP that is located 421 bp from F9 Malmö
in intron 5 (Table 1). The minor allele frequency and risk
estimate for the association between rs422187 and deep
vein thrombosis was similar to that of F9 Malmö as LD
between rs422187 and the F9 Malmö SNP was high
(r2=0.94). We did not find any haplotype of adjacent SNPs
(data not shown) that was more strongly associated with
deep vein thrombosis in LETS or MEGA-1 than F9 Malmö
or rs422187.
F9 Malmö and factor IX antigen level
We investigated whether the association between F9
Malmö and deep vein thrombosis could be explained by
an association between F9 Malmö and factor IX antigen
levels. Among the male control subjects from LETS,
MEGA-1 and MEGA-2 for whom factor IX antigen levels
were measured we did not find a difference in factor IX
level between the A and the G genotype (Table 2). 
F9 Malmö and factor IX activation
We investigated whether the association between F9
Malmö and deep vein thrombosis could be explained by
differential activation of factor IX. Among men of NPHS-
II for whom factor IX activation peptide levels were avail-
Figure 1. Combined analysis
of F9 Malmö with deep vein
thrombosis in men and
women.
Figure 2. In the selected
region on the X chromosome
(positions 138,404,951 to
138,494,063), 48 SNPs with
MAF>0.02 were genotyped
in the HapMap CEPH popula-
tion. The figure represents
pairwise linkage disequilibri-
um (r2) between the 48
SNPs. High r2 values are rep-
resented as black squares,
fading to gray and white as
linkage disequilibrium
becomes weaker. Based on
these r2 values, 18 tag SNPs
were selected of which 15
were genotyped in LETS
(black triangles). In addition,
we selected 14 candidate
SNPs (gray triangles), of
which one (rs2235708) was
located outside the selected
region. The arrow indicates
F9 Malmö (rs6048). 
Men (G vs. A)
LETS
MEGA-1
MEGA-2
Combined
0.58 (0.36-0.91)
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able we compared the mean activation peptide levels
between the A and G genotypes. There was no evidence
of lower levels of factor IX activation peptide in men with
the F9 Malmö genotype (Table 2).
F9 Malmö and endogenous thrombin potential
We also investigated the association between F9
Malmö and deep vein thrombosis through measuring the
endogenous thrombin potential. In the test performed in
LETS, coagulation is initiated via the extrinsic pathway.
Among the male control subjects of LETS for whom
endogenous thrombin potential was measured, we found
no difference between F9 Malmö genotypes (Table 2).
The LETS, MEGA and NPHS-II studies had sufficient
power to detect small differences in factor IX or factor IX
activation peptide levels between F9 Malmö genotypes A
and G. The combined LETS and MEGA factor IX antigen
level assays had a standard deviation of 17 U/dL and the
combined study had 90% power to detect mean factor IX
antigen level differences of 0.18 standard deviations (3.1
U/dL) or greater. The factor IX activation peptide assay
had a standard deviation of 75 pmol/L and the study had
90% power to detect mean factor IX activation peptide
level differences of 0.25 standard deviations (19 pmol/L)
or greater. The endogenous thrombin potential assay had
a standard deviation of 348 Nm.min and the study had
90% power to detect mean thrombin potential differ-
ences of 0.55 standard deviations (190 Nm.min) or
greater.
Discussion
We investigated whether the previously reported asso-
ciation between F9 Malmö and deep vein thrombosis
could be explained by linkage disequilibrium with SNPs
F9 Malmö, factor IX and deep vein thrombosis
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Table 1. Gene variants in F9 region and risk of deep vein thrombosis in LETS and MEGA-1.
rs number Position (chr X) Study r2 with F9 Malmö MAF (allele) OR* (95 % CI) p
rs4829996 138418800 LETS 0.36 0.36 (A) 0.67 (0.43-1.05) 0.084
rs7055668 (T) 138427049 LETS 0.02 0.08 (G) 0.92 (0.43-1.97) 0.835
rs411017 138439768 LETS 0.22 0.39 (A) 0.66 (0.43-1.01) 0.058
rs378815 (T) 138439863 LETS 0.01 0.39 (T) 0.67 (0.44-1.03) 0.067
rs3817939 (T) 138440752 LETS 0.04 0.02 (G) 0.67 (0.11-4.04) 0.659
rs371000 (T) 138443187 LETS 0.04 0.44 (C) 1.14 (0.76-1.70) 0.536
rs4149674 (T) 138444467 LETS 0.62 0.38 (T) 0.74 (0.48-1.14) 0.177
rs392959 (T) 138449920 LETS 0.02 0.08 (T) 1.07 (0.52-2.18) 0.855
rs398101 138451623 LETS 0.82 0.34 (G) 0.61 (0.39-0.96) 0.031
MEGA-1 0.85 0.33 (G) 0.83 (0.66-1.03) 0.094
rs4149755 138451778 LETS 0.03 0.06 (A) 1.42 (0.63-3.17) 0.395
rs4149758 138455143 LETS 0.19 0.08 (A) 0.73 (0.32-1.62) 0.434
rs374988 (T) 138458881 LETS 0.03 0.07 (G) 1.00 (0.45-2.22) 1.000
rs422187 138460525 LETS 0.95 0.33 (C) 0.61 (0.39-0.97) 0.035
MEGA-1 0.93 0.34 (C) 0.77 (0.61-0.96) 0.022
rs6048 (Malmö) (T) 138460946 LETS NA 0.33 (G) 0.58 (0.36-0.91) 0.017
MEGA-1 NA 0.32 (G) 0.79 (0.63-1.00) 0.046
rs4149759 (T) 138462720 LETS 0.08 0.09 (C) 0.74 (0.35-1.58) 0.439
rs413957 138465182 LETS 0.45 0.24 (G) 0.58 (0.35-0.96) 0.035
MEGA-1 0.45 0.23 (G) 0.83 (0.65-1.07) 0.159
rs4149761 (T) 138467129 LETS 0.01 0.01 (T) 0.00 − 0.999
rs4149730 (T) 138467398 LETS 0.01 0.03 (T) 0.99 (0.31-3.14) 0.993
rs421766 138468258 LETS 0.43 0.24 (C) 0.56 (0.33-0.94) 0.028
MEGA-1 0.47 0.22 (C) 0.85 (0.65-1.09) 0.196
rs4149762 (T) 138469863 LETS <0.01 0.05 (A) 1.76 (0.78-3.95) 0.171
rs370713 138470059 LETS 0.45 0.25 (C) 0.57 (0.34-0.95) 0.031
MEGA-1 0.46 0.22 (C) 0.85 (0.66-1.10) 0.220
rs4149749 138470891 LETS 0.00 0.00 (T) NA − −
rs4149763 138472372 LETS 0.00 0.00 (A) NA − −
rs440051 (T) 138472583 LETS 0.43 0.24 (A) 0.61 (0.36-1.00) 0.052
rs434144 138474091 LETS 0.40 0.26 (G) 0.50 (0.30-0.84) 0.009
MEGA-1 0.44 0.23 (G) 0.86 (0.67-1.10) 0.233
rs17342358 (T) 138482244 LETS <0.01 0.01 (A) 0.00 − 0.999
rs5907573 (T) 138489652 LETS 0.01 0.45 (T) 1.21 (0.81-1.81) 0.355
rs3128282 138490821 LETS 0.01 0.44 (C) 1.26 (0.84-1.88) 0.262
rs2235708 138506410 LETS <0.01 0.01 (A) 0.00 − 0.999
(T): tag SNP; MAF: minor allele frequency; *OR is the odds ratio for the minor relative to the major allele; NA: not applicable,minor allele not observed.
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that had a stronger association with deep vein thrombosis
than F9 Malmö. We also studied whether factor IX anti-
gen levels, factor IX activation peptide or endogenous
thrombin potential differed by F9 Malmö genotype,
which would provide a biological explanation for the
association with deep vein thrombosis. However, the
present results did not support any of these hypotheses.
The OR for the association of F9 Malmö with deep vein
thrombosis was slightly lower in men than in women of
all three studies, and broader confidence intervals were
observed in women. 
We did not identify any SNP that was more strongly
associated with deep vein thrombosis than F9 Malmö in
LETS and MEGA-1 among 29 SNPs we genotyped in the
F9 region. For 3 SNPs initially selected for genotyping in
LETS we were unable to construct genotyping assays.
These 3 SNPs are unlikely to be responsible for the
observed association between F9 Malmö and deep vein
thrombosis since they were not in strong LD (r2<0.2) with
F9 Malmö in the HapMap CEPH population. A recent
study found that rs4149755 in the F9 gene was associated
with deep vein thrombosis in postmenopausal women.15
We included rs4149755 in our analysis in LETS, but
rs4149755 was not associated with deep vein thrombosis
in men (Table 1) or in women (data not shown). We also did
not find any haplotype that was more strongly associated
with deep vein thrombosis in both LETS and MEGA-1
than F9 Malmö. 
The lack of an association between F9 Malmö and fac-
tor IX antigen levels is consistent with the results of a pre-
vious study, where none of 27 SNPs including F9 Malmö
were associated with factor IX levels.14 In a recent analysis
in LETS, no association was observed either;29 the present
study also included the LETS and confirmed the findings
in the MEGA study, which has a much larger number of
samples. The combined analysis of LETS and MEGA had
sufficient power to detect small factor IX antigen level dif-
ferences between genotypes; the observed levels were
almost identical. In addition to factor IX antigen levels we
studied factor IX activation. This analysis did not yield an
explanation for the observed association between F9
Malmö and risk of deep vein thrombosis either. The
power calculations suggest that we can likely (90%
power) exclude differences of 19 pmol/L or greater, but we
cannot rule out smaller differences. We used an indirect
assay to estimate activation of factor IX. The plasma level
of the factor IX activation peptide is dependent on the
release of activation peptide that occurs when factor IX is
activated to factor IXa and the steady clearance rate of the
activation peptide in the kidneys.30 Direct measurements
of factor IX activation by tissue factor (TF):factor VIIa or
factor XIa might reveal effects on the activation of factor
IX caused by F9 Malmö. 
The endogenous thrombin potential is the end product
of the TF activation pathway and is therefore an alterna-
tive measure of the activity of factor IX or any other fac-
tor in the coagulation cascade. We found no evidence of
an association between F9 Malmö and thrombin poten-
tial, although we cannot rule out a small difference
between the genotypes.
If the associations of F9 Malmö with deep vein throm-
bosis observed in this study are replicated in future stud-
ies, the question remains by which mechanism F9 Malmö
reduces risk of deep vein thrombosis. Our study included
SNPs with minor allele frequencies of at least <2% and
was not designed to detect functional variants that are less
frequent. It is also possible that one or more of the
observed associations is the result of linkage disequilibri-
um with a low frequency variation. 
In conclusion, the Malmö SNP in F9, rs6048, was asso-
ciated with a 20% reduction in risk of deep vein thrombo-
sis in a combined analysis of men from LETS, MEGA-1
and MEGA-2. The association was not explained by link-
age disequilibrium with other SNPs in the F9 region. We
were not able to provide a biological explanation for the
association of F9 Malmö with deep vein thrombosis, as
we found no evidence for an association of F9 Malmö
with either factor IX antigen levels or activation of factor
IX, indirectly measured by factor IX activation peptide
plasma levels and by the endogenous thrombin potential.
Additional studies should focus on investigating direct
measurements of factor IX activation and on linkage dise-
quilibrium between F9 Malmö and a rare (minor allele fre-
quency 0.02) sequence variant.
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Table 2. Association of F9 Malmö (rs6048) with factor IX antigen level in
male control subjects of LETS and MEGA, with factor IX activation peptide in
NPHS-II participants and with endogenous thrombin potential in male con-
trol subjects of LETS.
F9 Malmö A F9 Malmö G Difference 
N Mean (sd) N Mean (sd) (95% CI)1
Factor IX antigen level (U/dL)
LETS 127 104 (17) 64 109 (24) 5 (-1 to 11)
MEGA-1 562 104 (17) 261 102 (18) -3 (-5 to 0)
MEGA-2 344 104 (15) 140 104 (18) 0 (-3 to 3)
Combined 1033 104 (17) 465 103 (19) 0 (-2 to 1)
Factor IX activation peptide (pmol/L)
NPHS-II 840 217 (78) 359 226 (85) 8 (-1 to 18)
Endogenous thrombin potential (Nm.min)
LETS 102 1657 (341) 55 1583 (361) -73 (-189 to 41)
1T-test.
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